Targeted Sequencing and Resequencing - Global Strategic Business Report

The global market for Targeted Sequencing and Resequencing was valued at US$7.4 Billion in 2025 and is projected to reach US$31.1 Billion by 2032, growing at a CAGR of 22.8% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Targeted Sequencing and Resequencing Market - Key Trends & Drivers Summarized

Why Are Researchers and Clinicians Prioritizing Targeted Sequencing Over Broader Genomic Approaches?

Targeted sequencing and resequencing are gaining widespread adoption as powerful alternatives to whole-genome and transcriptome sequencing due to their ability to focus on specific genomic regions of interest with exceptional accuracy, efficiency, and cost-effectiveness. Unlike whole-genome approaches, which require significant data processing, storage, and interpretation of vast amounts of non-essential information, targeted sequencing enables scientists to zero in on known disease-associated genes, hotspots, or mutations - yielding clinically actionable results faster and with less computational burden. This precision-driven strategy is especially valuable in diagnostics, where time-sensitive and cost-sensitive tests are needed to inform therapeutic decision-making, such as in oncology, rare disease screening, and pharmacogenomics. Targeted resequencing, in particular, plays a vital role in studying genomic variability among individuals or populations by focusing on previously identified loci, making it an essential tool for population genetics, evolutionary biology, and mutational studies. These approaches also offer deep coverage of selected regions, enabling the detection of low-frequency variants that might be missed with broader sequencing. The flexibility to customize gene panels, the compatibility with degraded samples such as FFPE tissues, and the streamlined data interpretation workflows are further contributing to the increasing reliance on targeted strategies. As the healthcare sector moves toward personalized and precision medicine models, targeted sequencing and resequencing are providing the granularity, scalability, and relevance that researchers and clinicians need to drive impactful discoveries and informed clinical decisions.

How Are Advancements in Technology Enhancing the Capabilities of Targeted Sequencing?

The rapid evolution of sequencing technologies, library preparation kits, and bioinformatics pipelines is significantly enhancing the accuracy, speed, and flexibility of targeted sequencing and resequencing workflows. Next-generation sequencing (NGS) platforms now offer ultra-deep sequencing capabilities with higher throughput, lower error rates, and shorter run times, allowing researchers to interrogate specific genomic regions at single-nucleotide resolution. Hybrid capture and amplicon-based enrichment techniques are becoming more refined, offering high specificity and minimal off-target noise, even in low-input or damaged samples. Improvements in probe design, indexing, and barcoding are enabling the multiplexing of hundreds of samples in a single run without compromising data quality. Emerging long-read technologies are complementing short-read methods, allowing for better resolution of structural variants, repeat regions, and complex genomic rearrangements in targeted regions. Automated workflows and liquid-handling robotics are improving reproducibility and minimizing human error, which is particularly valuable in clinical and high-throughput research labs. On the data analysis side, machine learning algorithms and AI-powered annotation platforms are transforming variant calling, interpretation, and visualization - making it easier to identify clinically relevant mutations and prioritize actionable results. Cloud-based storage and analysis solutions are also becoming more integrated, enabling real-time collaboration, regulatory compliance, and efficient data sharing across research institutions. Additionally, targeted panels are being tailored for specific disease applications, including oncology, cardiogenetics, neurogenetics, and infectious diseases, providing fit-for-purpose diagnostic and research tools. These technological strides are expanding the versatility of targeted sequencing, ensuring it remains a foundational technique in both research and clinical genomics.

Where Is Targeted Sequencing and Resequencing Being Applied, and How Are Use Cases Evolving?

The applications of targeted sequencing and resequencing span a growing array of disciplines, from clinical diagnostics and pharmacogenomics to agricultural genomics and evolutionary biology. In healthcare, targeted sequencing panels are being widely used in oncology to identify driver mutations, guide targeted therapies, and monitor treatment resistance. Liquid biopsy-based tests using targeted panels are gaining traction for non-invasive cancer monitoring and minimal residual disease detection. In rare disease diagnosis, especially for genetically heterogeneous conditions, targeted resequencing enables clinicians to focus on curated sets of genes to improve diagnostic yield while keeping costs manageable. Infectious disease specialists use targeted sequencing to monitor pathogen evolution, resistance gene spread, and outbreak tracking. In pharmacogenomics, panels targeting drug metabolism genes are used to predict patient responses and personalize therapy plans. Beyond human health, plant and animal breeders use targeted sequencing to identify and track desirable traits, support marker-assisted selection, and protect biodiversity. In microbial ecology, researchers use targeted resequencing of specific 16S, 18S, or ITS regions to profile complex communities and study microbial interactions. Population geneticists use targeted resequencing to study ancestral lineages, disease predisposition, and gene-environment interactions across different cohorts. The utility of targeted approaches is also expanding in forensics, where customized panels are used for identity verification, kinship analysis, and mixture resolution. As regulatory standards evolve and NGS becomes more embedded in routine practice, targeted sequencing and resequencing are becoming go-to solutions for laboratories and organizations aiming to maximize scientific yield while minimizing costs and complexity.

What’s Fueling the Global Growth of the Targeted Sequencing and Resequencing Market?

The global market for targeted sequencing and resequencing is being propelled by a combination of rising demand for precision medicine, improvements in sequencing technology, the growing burden of chronic and genetic diseases, and the need for cost-effective genomic solutions. Healthcare systems worldwide are prioritizing rapid, accurate, and clinically relevant diagnostics, which targeted panels are uniquely positioned to deliver. The rising incidence of cancer, rare disorders, and infectious disease outbreaks is pushing demand for fast, high-confidence testing that can guide treatment and containment strategies. Regulatory approvals of panel-based diagnostics and increasing reimbursement support are encouraging clinical adoption across major markets. In the research sector, expanding government and private investment in genomics is supporting the use of targeted methods for high-impact projects, such as biobanking, large cohort studies, and precision agriculture initiatives. The emergence of turnkey sequencing solutions - complete with pre-validated panels, automated prep kits, and integrated analysis software - is lowering the barrier to entry for smaller labs and decentralized facilities. Academic-industrial partnerships are accelerating innovation in disease-specific panel development, ensuring a steady pipeline of relevant solutions tailored to emerging clinical and research needs. Additionally, as global emphasis on data security and compliance grows, cloud-based platforms and secure data pipelines are making it easier to deploy targeted sequencing in regulated environments. The scalability, affordability, and growing range of applications for targeted sequencing and resequencing ensure that this market will continue expanding rapidly - anchored in its ability to deliver focused, high-value genomic insights across disciplines.

Report Scope

The report analyzes the Targeted Sequencing and Resequencing market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Technology (Sequencing, Re-Sequencing); Type (DNA-based targeted sequencing, RNA-based targeted sequencing); Application (Clinical application, Plant & animal sciences, Drug development, Others); End-Use (Hospitals & Clinics, Academic research, Others)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Sequencing segment, which is expected to reach US$21.8 Billion by 2032 with a CAGR of a 24.9%. The Re-Sequencing segment is also set to grow at 18.7% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $2.0 Billion in 2025, and China, forecasted to grow at an impressive 29.4% CAGR to reach $7.6 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Targeted Sequencing and Resequencing Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Targeted Sequencing and Resequencing Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Targeted Sequencing and Resequencing Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Agilent Technologies, Inc., Azenta Life Sciences (GENEWIZ), BGI Genomics, Bio-Rad Laboratories, Inc., CD Genomics and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Targeted Sequencing and Resequencing market report include:

• Agilent Technologies, Inc.
• Azenta Life Sciences (GENEWIZ)
• BGI Genomics
• Bio-Rad Laboratories, Inc.
• CD Genomics
• CosmosID
• DNASTAR, Inc.
• Element Biosciences
• Eurofins Genomics
• F. Hoffmann-La Roche Ltd
• GATC Biotech AG
• Genomatix GmbH
• Illumina, Inc.
• Integrated DNA Technologies, Inc.
• Macrogen, Inc.
• New England Biolabs
• Novogene Corporation
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• Paragon Genomics
• PerkinElmer, Inc.
• PierianDx

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.